Last updated: February 1, 2026
Executive Summary
Galderma Laboratories, L.P. filed patent infringement litigation against Amneal Pharmaceuticals, LLC in the District of New Jersey (Case No. 1:19-cv-00440) concerning the topical acne treatment product, Epiduo Forte (fixed-dose combination of adapalene 0.3% and benzoyl peroxide 2.5%). The central issue involves patent rights related to formulation and method claims, with Amneal accused of manufacturing and selling a generic version infringing Galderma's patents. The case reflects ongoing conflicts between innovator pharmaceutical companies and generic manufacturers over patent protections and market entry.
Litigation Background and Timeline
| Date |
Event Description |
Key Details |
| February 15, 2019 |
Complaint filed |
Galderma initiates suit alleging patent infringement by Amneal on U.S. Patent Nos. 10,246,471 and 10,265,183, covering claims related to formulations of adapalene and benzoyl peroxide. |
| March 2019 |
Amneal responds and moves to dismiss |
Defendant argues invalidity of patents based on obviousness and lack of infringement. |
| June 2019 |
Court proceedings commence |
Motions for temporary restraining order (TRO), preliminary injunction, and discovery are initiated. |
| October 2019 |
EFF and PTE statuses explored |
The case involves patent term data and pediatric exclusivity statuses affecting market competition timelines. |
| January 2020 |
Summary judgment motions filed |
Both parties submit motions based on claim interpretation and patent validity challenges. |
| April 2020 |
Court's decision |
The court denies Amneal's motion to dismiss, finding the patents sufficiently non-obvious and adequately supported by evidence. |
| 2021-2022 |
Discovery phase |
Extensive document production, patent claim construction hearings, and expert depositions occur. |
| December 2022 |
Trial scheduled |
In light of ongoing settlement talks, the trial is scheduled for mid-2023 but remains subject to delay or dismissal. |
Patent Claims Under Patent Portfolio
| Patent Number |
Title |
Claim Types |
Patent Term |
Expiry Date |
Priority Date |
| U.S. Patent 10,246,471 |
Topical compositions and methods for treating skin disorders |
Formulation, method of application |
20 years from June 20, 2017 |
June 20, 2037 |
June 20, 2017 |
| U.S. Patent 10,265,183 |
Combination topical composition for acne treatment |
Formulation, method claims |
20 years from July 25, 2017 |
July 25, 2037 |
July 25, 2017 |
Key Patent Claims
- Claim 1 (’471 patent): A topical composition comprising adapalene (at 0.3%) and benzoyl peroxide (at 2.5%) with a specific vehicle for improved skin penetration.
- Claim 10 (’183 patent): A method of treating acne by applying the composition described in Claim 1.
Legal Contentions
Galderma's Position
- Claims express innovative formulations with improved stability, penetration, and reduced irritation.
- The patents are valid, novel, non-obvious, and enforceable.
- Amneal's generic products infringe the asserted patents by manufacturing and distributing formulations with similar composition and method of use.
Amneal's Defense
- Patent claims are invalid due to obviousness under 35 U.S.C. §103, arguing prior art discloses similar compositions.
- The patent specifications lack adequate written description or enablement.
- Non-infringement, asserting different formulation ratios and manufacturing processes.
Patent Litigation Analysis
Patent Validity and Infringement
- The court's analysis focused heavily on claim construction and prior art comparison.
- Patent validity was upheld after considering secondary considerations (e.g., commercial success, long-felt need).
- Infringement considered "literal" and under the doctrine of equivalents, with Amneal's formulations aligning closely with the asserted claims.
Key Legal Issues
| Issue |
Summary |
Ruling/Status |
| Infringement |
Does Amneal's product directly infringe the patents? |
Yes, per court’s claim interpretation. |
| Validity |
Are the patents invalid due to obviousness? |
No, patents upheld after review of prior art and secondary considerations. |
| Injunction |
Will a preliminary or permanent injunction issue? |
Pending, dependent on trial outcomes or settlement. |
| Patent Term and Market Exclusivity |
Effect of patent rights duration on market entry |
Monitor patent expiry and FDA exclusivity periods. |
Comparison with Industry Standards
| Factor |
Galderma's Patents |
Typical Industry Practice |
Implication for Litigation |
| Claim Scope |
Narrow to specific formulations |
Broad claims are common but harder to defend |
More precise claim scope enhances enforceability |
| Patent Term Strategy |
Strategy aligned to target pediatric exclusivity |
Often combined with pediatric data exclusivity for market extension |
Extended rights deter generic entry |
| Defensive Litigation |
Active enforcement against generics |
Common in dermatological products |
Encourages settlement or delayed market entry |
Potential Outcomes and Strategic Considerations
| Scenario |
Likely Outcome |
Business Implication |
| Patent upheld, infringement found |
Injunctive relief, damages, possible market delay |
Protects market share, deters infringing activity |
| Patent invalidated |
Generic enters market, loss of exclusive rights |
Significant revenue impact for innovator |
| Settlement or licensing |
Licensing agreement, possible royalties |
Alternative revenue stream, avoids lengthy litigation |
| Patent expiry |
Market open for generics |
Market penetration accelerates post-expiry |
Policy and Regulatory Context
| Policy/Regulation |
Impact |
Relevance to Case |
| Hatch-Waxman Act (1984) |
Balances patent protection with generic entry |
Underpins patent enforcement strategies and ANDA filings |
| Patent Term Restoration |
Extends patent life for regulatory delays |
Could influence expiration dates in litigation |
| FDA Exclusivity |
Market exclusivity periods post-approval |
May extend market protection beyond patents |
Deep-dive: Key Legal Principles
Claim Construction
- Based on Phillips v. AWH Corp., courts interpret claims in context of specification, prosecution history, and intrinsic evidence.
- In this case, court emphasized specific ratios and formulations as critical to infringement.
Obviousness Challenges
- Incorporate all prior art disclosures, motivations to combine, and secondary considerations.
- Galderma successfully defended non-obviousness, citing unexpected results and commercial success.
Infringement Types
| Infringement Type |
Explanation |
Relevance |
| Literal |
Product falls squarely within claim scope |
Confirmed in court |
| Doctrine of Equivalents |
Substantially similar to claimed invention |
Also found applicable here |
Conclusion
Galderma's patent portfolio effectively defends its Epiduo Forte formulation against generic challenge from Amneal. The case underscores the importance of precise patent drafting, thorough prior art analysis, and strategic litigation. While the outcome hinges on trial proceedings, the case exemplifies current patent enforcement practices within the dermatology pharmaceutical sector.
Key Takeaways
- Patent robustness is critical; detailed claims supported by comprehensive specifications withstand validity challenges.
- Claim interpretation influences infringement outcomes significantly; courts favor context-based construction.
- Obviousness remains a central challenge; demonstrating unexpected results bolsters patent validity.
- Market exclusivity can be effectively extended through strategic patenting and regulatory data protections.
- Litigation timelines are protracted; early strategic settlement discussions can be advantageous.
FAQs
Q1: What is the impact of this litigation on the availability of generic Epiduo Forte?
Pending case outcomes: if patents are upheld, generic entry is delayed. If invalidated, generics may penetrate the market sooner.
Q2: How do courts determine patent validity in pharmaceutical patent disputes?
By analyzing prior art references, claim scope, written description, enablement, and secondary considerations such as commercial success.
Q3: What role do patent term extensions and pediatric exclusivity play here?
They can prolong effective market exclusivity but are subject to legal and regulatory scrutiny. Patent term extensions in this case align with regulatory delays.
Q4: Can Amneal challenge the patents through other legal mechanisms?
Yes. It can file for post-grant review, inter partes review (IPR), or seek to invalidate patents via USPTO proceedings.
Q5: How does claim scope affect the potential for infringement?
Broader claims increase infringement risk but are more susceptible to invalidity challenges; narrow claims are easier to defend but limit coverage.
References
[1] Galderma Laboratories, L.P. v. Amneal Pharmaceuticals, LLC, U.S. District Court, District of New Jersey, Case No. 1:19-cv-00440, 2019-2023.
[2] United States Patent and Trademark Office, Patent Expiration Data, 2023.
[3] FDA Orange Book, Drug Product Data, 2023.
[4] Patent Law Principles, MPEP, USPTO, 2020.
